Truist Securities Maintains Buy on Dianthus Therapeutics, Raises Price Target to $128
Truist Securities analyst Danielle Brill maintains Dianthus Therapeutics (NASDAQ:DNTH) with a Buy and raises the price target from $110 to $128.
Stocks · News reference
Citigroup Initiates Coverage On Dianthus Therapeutics with Buy Rating, Announces Price Target of $156
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
HC Wainwright & Co. Maintains Buy on Dianthus Therapeutics, Raises Price Target to $158
HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Dianthus Therapeutics (NASDAQ:DNTH) with a Buy and raises the price target from $130 to $158.
Wedbush Maintains Outperform on Dianthus Therapeutics, Raises Price Target to $122
Wedbush analyst Laura Chico maintains Dianthus Therapeutics (NASDAQ:DNTH) with a Outperform and raises the price target from $105 to $122.